69 results about "Immune Cell Function" patented technology

The invention discloses an immunocyte culture medium, and a culture method and application of immunocytes. The immunocyte culture medium is composed of one or more selected from the group consisting of amino acids, vitamins, salts, lipids or polypeptide, and one or more selected from the group consisting of cytokines or antibodies; the immunocyte culture medium can quickly amplify different types of immunocytes, enables the amplification speed of the immunocytes to be increased by 3 to 5 times than the amplification speed of the immunocytes cultured with a conventional culture medium, and prolongs passage times; meanwhile, the immunocytes cultured by the immunocyte culture medium provided by the invention can maintain good immunocyte functions and exert effects including, but not limited to, anti-cancer effect and anti-aging effect, so the immunocytes have good application prospects.

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function.

The invention provides a kit and a method for comprehensively evaluating functions of immune cells in human peripheral blood. The kit for comprehensively evaluating the functions of the immune cells in the human peripheral blood comprises an anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD56, CD57, CD94, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, P30, P46, NKG2D, KIR (NKB1), gamma delta, v delta 2, IgD and IgM antibodies, wherein the antibodies carry fluorescein labels. The kit can be used for comprehensively evaluating the functions of the immune cellsin the human peripheral blood, and is convenient and safe to use.

Methods for generating highly enriched Th1 / Tcl and Th2 / Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.

The invention discloses a transgenic T cell of a targeted CD30 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding the targeted CD30 antigen, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell containing a recombinant lentivirus expression vector (including a gene which is shown as SEQ ID NO:2 and encodes the targeted CD30 antigen and shRNA of a targeted PD1 gene or / and shRNA of a targeted CTLA4 gene); the primary cell is CD4+T cell or CD8+T cell. A preparation method comprises the following steps: firstly, carryingout lentivirus infection on the CD4+T cell or the CD8+T cell; secondly, mixing gRNA, CRISPR-cas9mRNA and HDR, and carrying out electroporation recombination on the T cell to obtain a finished product.According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are knocked out or silenced, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

The invention belongs to the technical field of Chinese herbal medicine and relates to externally applied medicine for treating beriberi and a preparation method of the externally applied medicine. The externally applied medicine solves the technical problems that the compatibility is not reasonable enough and the curative effect is poor in the prior art. The externally applied medicine comprises the following components in parts by weight: 1-3 parts of fructus cnidii, 4-6 parts of folium artemisiae argyi, 1-3 parts of radix angelicae pubescentis, 2-4 parts of grassleaf sweelflag rhizome, 2-4 parts of rhizoma atractylodis, 8-12 parts of mint, 4-6 parts of amoorcorn tree bark, 4-6 parts of radix scutellariae, 2-4 parts of radix sophorae flavescentis, 1-3 parts of fructus kochiae, 4-6 parts of oriental wormwood, 2-4 parts of gardenia, 12-18 parts of honeysuckle, 8-12 parts of ginger, 2-4 parts of tea, 1-3 parts of radix stemonae, 4-6 parts of Chinese lobelia, 4-6 parts of tuber fleeceflower stems, and 10-14 parts of rice vinegar. The externally applied medicine has the advantages that the externally applied medicine has the effects of alleviating pain, stopping pyemia, sterilizing, preventing inflammation and viruses, removing necrotic tissues, promoting tissue regeneration and improving immune cell functions. In addition, the externally applied medicine is simple to manufacture, low in cost, good in effect and suitable for industrial processing and production.

The invention discloses a gene for encoding anti-BCMA chimeric antigen receptor. The nucleotide sequence of the gene is represented by SEQ ID NO:2. The invention also discloses a recombinant expression vector containing the gene, and a myeloma BCMA antigen-targeted transgenic T cell. The transgenic T-cell is a primitive cell containing the recombinant expression vector and knocked out of a PD1 gene or / and a CTLA4 gene, or is a primitive cell with the chromosome being integrated with the gene for encoding anti-BCMA chimeric antigen receptor and knocked out of tbe PD1 gene or / and the CTLA4 gene.A preparation method of the transgenic T-cell comprises the following steps: mixing of gRNA, CRISPR-cas9 mRNA and HDR mix, and electrotransformation recombination of the T cell. The invention furtherdiscloses an application of the myeloma BCMA antigen-targeted transgenic T cell in the preparation of drugs for treating multiple myeloma. In the construction process of carT of, a recognition sequence of EGFR is introduced, EGFR monoclonal antibody Cetuximab is used to eliminate a carT cell if necessary, and PD1 and CTLA4 genes are knocked out to relieve the inhibition effect of the PD1 and CTLA4 genes on the carT cell and enhance the overcoming effect of the carT cell on the inhibition of the tumor microenvironment on immune cell functions.

The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and / or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and / or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and / or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormon.

The invention provides an immune function assessment kit and assessment method for patients with an autoimmune disease. The immune function assessment kit for the patients the autoimmune disease comprises anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD57, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, IgD, and IgM antibodies, and all antibodies referred carry fluorescein labels. The kit can be used for carrying out comprehensive assessment to the function of immune cells of the patients with the autoimmune disease, and usage is convenient and safe.

The invention discloses a killer immune cell culturing method and application thereof. The method is a novel technology for culturing, activating and amplifying peripheral blood mononuclear immune cells into tumor killer cells, and the tumor killing capacity of T cells is enhanced by adding a PD-1 antibody to inhibit combination of PD-1 on the T cells and tumor cells in the late period of cell culturing or before transfusion through the characteristic that the inhibition effect of an immunosuppression target point on the immune cell functions is inhibited by adding an immune check point antibody; the cells cultured through the method have CTL cells which are targeted on the tumor antigen specificity in high proportion and also have the high capacity on killing the tumor cells. In this way, not only is the defect of an existing technology on the CTL cell culturing effect overcome, but also limitation of an immune checking point on the T cell functions is fully utilized and relieved, therefore, the tumor cell killing capacity of the prepared cells is improved, and the efficacy of the prepared cells on clinical cancer treatment is improved.

The invention provides a kit for assessing a function of cytotoxic immune cells in human peripheral blood and an assessment method. The kit for assessing the function of cytotoxic immune cells in human peripheral blood provided by the invention comprises an anti-human CD3 antibody, an anti-human CD8 antibody, an anti-human CD45RA antibody, an anti-human CCR7 antibody, an anti-human CD28 antibody,an anti-human CD38 antibody, an anti-human CD57 antibody, an anti-human HLA-DR antibody, an anti-human PD-1 antibody, an anti-human CD56 antibody, an anti-human CD94 antibody, an anti-human NKP30 antibody, an anti-human NKP46 antibody, an anti-human NKG2D antibody, an anti-human KIR antibody, an anti-human Gamma Delta antibody and an anti-human V Delta 2 antibody, wherein all the antibodies are labeled by fluorescein. The kit for assessing the function of cytotoxic immune cells in human peripheral blood provided by the invention can be used for comprehensively assessing the immunity function of the cytotoxic immune cells in human peripheral blood, and is convenient and safe for use.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

The invention discloses a transgenic T cell of a targeted CD19 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:8 and encoding the targeted CD19 antigen in chromosome, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding a targeted PSA-NCAM receptor ,and a gene shown asSEQ ID NO:8 and encoding the targeted CD19 antigen in the chromosome; the primary cell is CD4+T cell or CD8+T cell. The invention also discloses application of the transgenic T cell of the targeted CD19 antigen in preparation of a medicine for treating malignant B cell lymphoma. According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are silenced or knocked out, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

This invention provides a method of improving glutathione (GSH) concentrations, both intra and extra-cellularly, in animals, thereby improving the cellular function of the immune and other bodily organ functions. The invention is directed toward a composition treating glutathione deficient animals which comprises N-acetylcysteine; vitamin C; L-glutamine; Silymarin; Cordyceps sp.; alpha-lipoic acid; and a pharmaceutically acceptable systemic carrier. The composition of the invention optionally comprises one or more of the following quercitin; N-acetyl-D-glucosamine; and dietary protein.

The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and / or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.

A supplement for administering to a human, or other mammals, includes a carotenoid material, a nicotinamide material, a zinc source material, and a water soluble extract material of an Uncaria species. The supplement can be in a form for oral administration, particularly in a form of nutritional drink, or in a formulation for parenteral administration. Also disclosed is a method of treating a human including administering to an individual the supplement daily in amounts effective, in combination, to improve the individual's resistance to DNA damage, enhance DNA repair capacity, stimulate immune cell function, and inhibit tumor cell growth.

The invention provides an immune cell function evaluation kit and evaluation method for a tumor patient. The immune cell function evaluation kit for the tumor patient comprises an anti-human CD3 antibody, an anti-human CD4 antibody, an anti-human CD8 antibody, an anti-human CD25 antibody, an anti-human CD28 antibody, an anti-human CD38 antibody, an anti-human CD56 antibody, an anti-human CD57 antibody, an anti-human CD94 antibody, an anti-human CD127 antibody, an anti-human CD45RA antibody, an anti-human CCR7 antibody, an anti-human HLA-DR antibody, an anti-human PD-1 antibody, an anti-human NKP30 antibody, an anti-human NKP46 antibody, an anti-human NKG2D antibody, an anti-human KIR antibody, an anti-human gamma-sigma antibody and an anti-human Vsigma2 antibody. All the above antibodies carry fluorochrome labels. The kit can be used for comprehensively evaluating an immune cell function of the tumor patient and is convenient and safe to use.

The invention discloses a construction method and application of a CD45-DTR transgenic mouse for regulating and removing immune cells by diphtheria toxin. The preparation method comprises the following steps: performing enzyme digestion linearization on BAC Cone CD45-DTR; introducing BALB / C ES cells of mouse embryonic stem cells by using an electroporation method to obtain the BALB / C ES cells withIRES-DTR being inserted into the site 1 of the CD45 exon; and then, constructing a CD45-DTR transgenic mouse with the IRES-DTR being inserted into the site 1 of the CD45 exon through a blastocyst injection method by utilizing the BALB / C ES cells. The invention provides a novel construction method of a mouse model capable of inducing and selectively removing immune cells. The method can be widelyapplied to the fields of preparation of humanized mice, research of immune cell functions and the like.

The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue, and / or cells, by disrupting sex steroid signaling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signaling in the patient, is interrupted or ablated by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

Provided herein are fusion proteins that bind human CD8α, human CD8β, or human PD1 and comprise a mutant IL-2 polypeptide, as well as polynucleotides, host cells, compositions, and methods of use thereof.

The invention provides an antibacterial ceramic product, which comprises a main body layer, a glaze layer and energy mineral powder, wherein the glaze layer is in contact with the main body layer; and the energy mineral powder is dispersed into the main body layer or the glaze layer. The energy mineral powder is added to the antibacterial ceramic product and can release 4-16micron far infrared rays; the released far infrared rays can release heat; the pathological process of inflammation is removed through question and answer reaction of a neurohumour; the physiological balance state damaged in the past is restored; local and whole-body disease resistance is improved; the immunologic cell function is activated; the phagocytic function of white blood cells and reticuloendothelial cells is reinforced; the antibacterial and anti-inflammation effects are finally achieved, so that the antibacterial ceramic product provided by the invention has a healthcare effect; the preparation method of the antibacterial ceramic product provided by the invention is simple in process and easy to operate; and large-scale manufacturing production is facilitated.

The invention discloses a chimeric antigen receptor. The chimeric antigen receptor comprises: a) an extracellular target molecule binding motif; b) an intracellular signal transduction motif, which comprises at least one intracellular activation signal transduction motif, wherein the activation of the intracellular activation signal transduction motif at least depends on binding of the extracellular target molecule binding motif to a target molecule, and the intracellular activation signal transduction motif contains molecules or fragments with catalytic functional groups; and c) a transmembrane region motif for linking the extracellular target molecule binding motif and the intracellular signal transduction motif. The chimeric antigen receptor is combined with various means such as tumorimmunology, synthetic biology, molecular cell engineering and the like, an artificial molecular machine which is based on an immune checkpoint signal path PD-1 / PD-L1 and has a function of coding and regulating immune cells is established and applied, and the chimeric antigen receptor has the same advantages as both an immune checkpoint inhibitor and CART cell therapy and provides a solution for improving solid tumor treatment.

The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and / or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.

The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to a subject a population of immune cells that express an exogenous enzyme that facilitates immune cell function in a nutrient-poor environment. Other embodiments of the invention include methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to the subject an effective amount of an agent that provides a one-carbon unit (e.g., formate) and an agent that promotes an anti-tumor response, and methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to a subject an effective amount of an agent that inhibits consumption of metabolic fuels by tumor cells. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an exogenous enzyme that enhances immune cell function in nutrient poor environments, and compositions comprising a nucleic acid expression construct encoding an inhibitor of glucose metabolism, and a pharmaceutically acceptable carrier or excipient.

The invention belongs to the technical field of medicines, and particularly relates to application of a combination of natural immune agonist and brain homeostasis regulatory protein in treating Alzheimer's disease. The brain homeostasis balance regulatory protein can pass through a blood brain barrier, so that homeostasis balance of brain metal ions is effectively regulated and controlled, homeostasis balance of active oxygen species is effectively inhibited, and toxic senile plaques are effectively reduced. The natural immune agonist can effectively regulate brain immune cell functions and reduce pathological features such as chronic brain inflammation. The combination of the brain homeostasis regulatory protein and the natural immune agonist can significantly improve the nerve cell morphology of hippocampus, inhibit nerve cell apoptosis, eliminate toxic amyloid deposition, improve the learning and memory ability of model mice, and prevent the development of Alzheimer's disease. Therefore, the combination of the brain homeostasis regulatory protein and the natural immune agonist has a wide application prospect in the aspect of treating Alzheimer's disease.

The invention relates to an external applied medicine for treating beriberi. The external applied medicine consist of the following Chinese herbal medicines in percentage by weight: 15 to 35 percent of glabrous greenbrier rhizome, 15 to 35 percent of yellowmouth dutchmanspipe root, 10 to 25 percent of trifoliate jewelvine root, 10 to 20 percent of Chinese gall and 7 to 15 percent of borax. The external applied medicine is developed through improvement on a descendant nostrum preparation and many years of clinical trials. The external applied medicine is an external applied ointment for treating beriberi and a pure Chinese medicinal preparation, and has the radical treatment effect on multiple kinds of beriberi. After seven days of use, beriberi can be cured and prevented from relapsing within three months. The external applied medicine has the good effect of pain relief, stop of pus and blood, sterilization, antitoinflammatory, antivirus, removal of putrefaction and promotion of tissue regeneration, and enhancement of immunocyte function; moreover, and the external applied medicine is easy to prepare and low in cost, has the excellent effect, and is applicable for industrial processing and production.